Abstract. Multidrug resistance (MDR) is a major concern when using chemotherapy for the treatment of patients with colorectal cancer. MDR modulators are agents that can reverse MDR and, thus, enhance the chemosensitivity of tumor cells. The development of MDR modulators can improve the therapeutic efficacies of MDR in cancer. However, few effective MDR modulators have been identified so far. Curcumin has been reported to be an effective compound in the reversal of MDR in colorectal cancer cells. However, the mechanisms associated with the reversal effect of curcumin on MDR and its regulation of target factors in MDR cells remain to be fully elucidated. 3-(4,5-dimethyl-2-thiazol)-2,5-diphenyltetrazolium bromide assays, flow cytometer apoptosis assays as well as mRNA and protein expression assays were performed in the present study, and the results confirmed the reversal effect of curcumin on HCT-8/5-Fu cells and provided evidence that activated nuclear factor erythroid 2-related factor (Nrf2) deficiency induced by the curcumin altered the B-cell lymphoma 2 (Bcl-2) associated X protein/Bcl-2 expression ratio, which led to the induction of apoptosis in HCT-8/5-Fu cells. These results indicated that Nrf2 may have a functional in the reversal effect of curcumin and contribute, at least in part, to the outcomes of chemotherapy in patients with MDR.
Introduction
Colorectal cancer is the fifth most common type of cancer and is the leading cause of cancer-associated mortality in China (1) . Chemotherapy is the main clinical therapeutic method for colorectal cancer in addition to surgery and radiotherapy (2) . However, the rapid development of chemoresistance in colorectal cancer cells, particularly in its multiple form as multidrug resistance (MDR), which can either be intrinsic or acquired, is a major obstacle to overcome for the successful treatment of colorectal cancer (3) . Identifying effective MDR modulators that are able to reverse MDR and can be used in combination with anticancer drug therapies has been a promising strategy to increase the success rate of chemotherapy. However, a number of MDR reversal agents frequently exhibited unacceptable levels of toxicity when they were administered at an effective dose in clinical trials (4) (5) (6) . These side effects have consequently limited their application in clinical settings. To overcome the MDR of colorectal cancer, it is essential to develop novel reversal compounds with higher efficacy and lower toxicity.
Curcumin is a natural product obtained from the dried rhizomes of Curcuma longa (turmeric), which has been used for centuries throughout Asian countries as a food additive, in cosmetics, and as a form of traditional Chinese medicine (7, 8) . It exhibits a wide range of pharmacological properties, including anti-inflammatory, anti-angiogenic, anti-oxidative and anticancer effects (9) (10) (11) . Previous studies have demonstrated that curcumin reversed MDR in various tumors, including gastric, hepatic, and cervical cancer (12, 13) . However, the mechanisms associated with the MDR reversal effect of curcumin and its targets remain to be fully elucidated.
In the present study, the key target and mechanism underlying the reversal effect of curcumin were investigated using the MDR HCT-8/5-Fu human colorectal cancer cell line. The results indicated that nuclear factor erythroid 2-related factor (Nrf2) may be critical in the MDR reversal effect of curcumin by promoting the apoptosis of HCT-8/5-Fu cells. Together with previously published data, these results suggest that curcumin may be suitable for the clinical treatments used in patients with MDR. Cell viability assay. The effect of drug treatments on cell viability was quantified using the 3-(4,5-dimethyl-2-thiazol)-2,5-diphenyltetrazolium bromide (MTT) assay. Cells in the exponential growth phase were trypsinized and seeded in 96-well plates at an initial density of 5,000 cells/well and then treated with the scheduled treatment of drugs (for curcumin: set 100 µM as the initial concentration, followed by 2-fold dilution for 10 concentrations; for 5-Fu: set 58.88 mM as the initial concentration, followed by 2-fold dilution for 13 concentrations). Complete RPMI-1640 medium without drugs was added to the blank wells. The control cells were treated with dimethyl sulfoxide (DMSO) only. Following incubation for 24 h, 10 µl MTT (Amresco, Inc., Solon, OH, USA) was added to each well and the cells were incubated at 37˚C for 4 h. The medium was then carefully removed and 150 µl DMSO was added, followed by gentle agitation. The optical density (OD) of the released color was read at 570 nm. The cell growth inhibition rate was calculated using the following formula: Growth inhibition rate = (OD value of control -OD value of test)/(OD value of control -OD value of blank) x 100%.
Materials and methods

Cell
MDR reversal assay.
A concentration of 10 µM curcumin, which was lower than the IC 10 value obtained following the MTT assay of curcumin alone in HCT-8/5-Fu cells, was designated as the reversal concentration of curcumin in the following experiments. The HCT-8/5-FU cells were plated in 96-well plates at an initial density of 5,000 cells/well and allowed to grow for 12 h. The cells were then pretreated with 10 µM curcumin for 4 h, followed by treatment with serial dilutions of 5-Fu for 24 h (set 58.88 mM as the initial concentration, followed by 2-fold dilution for 10 concentrations). The control cells were treated with 5-Fu alone. By performing the MTT assay, as described above, the IC 50 of each treatment was calculated. The reversal fold change was defined with the following ratio: IC 50 value of 5-Fu alone/IC 50 value of 5-Fu combined with curcumin.
Apoptosis assay. The HCT-8/5-Fu cells were divided into the following four groups: i) No treatment group (control); ii) 10 µM curcumin treatment group; iii) 10 mM 5-Fu treatment group; and iv) 10 µM curcumin + 10 mM 5-Fu treatment group. All cells (5x10 3 ) were plated on 6-well plates for 12 h, and then treated with curcumin or DMSO (control) for 4 h, followed by 5-Fu treatment for a further 24 h. All cell cultures were performed at 37˚C in an incubator containing 5% CO 2 . The cells were then harvested, washed twice with ice-cold PBS, and evaluated for apoptosis using a FITC-Annexin V Apoptosis Detection kit I (BD Biosciences, San Jose, CA, USA) and analyzed using a Novocyte flow cytometer (ACEA Biosciences, Inc., San Diego, CA, USA) with NovoExpress 1.2.4 software (ACEA Biosciences, Inc.). Analysis of apoptotic rates was performed using GraphPad Prism 5.0 software (GraphPad Software, Inc., San Diego, CA, USA).
RNA extraction and reverse transcription-quantitative polymerase chain reaction (RT-qPCR) analysis.
The drug treatments were performed as mentioned above. Total RNA was extracted using TRIzol reagent (Thermo Fisher Scientific, Inc.), and first strand cDNA was generated using the Reverse Transcription system (Takara Bio, Inc., Otsu, Japan; cat no. RR047A) in a 20 µl reaction containing 1 µg of total RNA. A 1 µl aliquot of cDNA was amplified using the SYBR-Green PCR Master mix (Takara Bio, Inc.; cat. no. RR820A) in each 20 µl reaction according to the manufacturer's instructions. The thermocycling conditions used for qPCR were as follows: 95˚C for 10 min; followed by 40 cycles at 95˚C for 5 sec, 60˚C for 30 sec and a 1 cycle dissociation stage at 95˚C for 15 sec, 60˚C for 1 min and 95˚C for 15 sec. qPCR was performed using the ABI StepOne plus Real-Time PCR system with the following primers: Nrf2, forward 5'-ATAGCTGAGCCCAG TATC-3' and reverse 5'-CATGCACGTGAGTGCTCT-3'; Kelch-like ECH associated protein 1 (Keap1), forward 5'-CT GGTATCTGAAACCCGTCTA-3' and reverse 5'-TGGCTTCT AATGCCCTGA-3'; B-cell lymphoma 2 (Bcl-2), forward 5'-TT CTTTGAGTTCGGTGGGGTC-3' and reverse 5'-TGCATATT TGTTTGGGGCAGG-3'; Bcl-2-associated X protein (Bax), forward 5'-TCCACCAAGAAGCTGAGCGAG-3' and reverse 5'-GTCCAGCCCATGATGGTTCT-3'; and GAPDH, forward 5'-AGAAGGCTGGGGCTCATTTG-3' and reverse 5'-AG GGGCCATCCACAGTCTTC-3'. The relative expression values of Nrf2, Keap1, Bcl-2 and Bax were calculated and normalized to GAPDH in each sample using the 2 -∆∆Cq method (14) . The experiments were performed in triplicate.
Western blot analysis. The whole cells were lysed with RIPA lysis buffer (Beyotime Institute of Biotechnology, Haimen, China; cat. no. P0013B). Protein quantification was performed using a BCA Protein Assay kit (Thermo Fisher Scientific, Inc.; cat. no. 23225), following which equal quantities of proteins (100 µg) were separated via a 4-20% gradient SDS-PAGE gel, and transferred onto a PVDF membrane. The membranes were blocked with 5% BSA (Merck KGaA) at room temperature for 2 h. Antibodies against the following proteins were used: Rabbit anti-NRF2 was purchased from Abcam (Cambridge, MA, USA; cat. no. ab62352); rabbit anti-Keap1, rabbit anti-Bcl-2, rabbit anti-Bax and rabbit anti-actin were purchased from Cell Signaling Technology, Inc. (Danvers, MA, USA; cat. nos. 8047, 4223, 5023 and 8457, respectively). All primary antibodies were used at a 1:1,000 dilution in 5% BSA together with the membranes and incubated at 4˚C overnight. Following three washes in TBS/0.1% Tween-20, the membranes were each probed with a secondary horseradish peroxidase-conjugated goat anti-rabbit antibody (Abcam; cat. no. ab6721) at a 5,000-fold dilution in 5% BSA. Following six washes with TBS/0.1% Tween-20, the immune complexes were incubated with ECL reagents (Thermo Fisher Scientific, Inc.; cat. no. 34577), and detected using the ChemiDoc™ Touch Imaging System (Bio-Rad Laboratories, Inc., Hercules, CA, USA). The resulting bands on the membranes were calculated and normalized to β-actin in each sample using ImageJ software (version 1.39u; National Institutes of Health, Bethesda, MD, USA).
Small interfering (si)-RNA and transfection. Nrf2 siRNA and a scramble non-targeting siRNA (siCtrl; negative control) were purchased from Biomics Biotechnologies Co., Ltd. (Nantong, China). The siRNA sequences were as follows: siNrf2, 5'-GA GACUACCAUGGUUCCAA-3'; and siCtrl, 5'-UUCUCCGA ACGUGUCACGU-3'. The siRNAs were transfected into cells using Lipofectamine 2000 ® reagent (Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol.
Statistical analysis.
The results are presented as the mean ± standard deviation of at least three independent experiments for each group. Statistical differences were determined by one-way analysis of variance with Holm's post hoc test for multiple comparisons or two-sample t-tests for independent samples using SPSS 19.0 software (IBM SPSS, Armonk, IL, USA). Linear mixed effects models were used in analyses in order to account for the correlations among correlated observations, including cell growth measured over time in cell culture. P<0.05 was considered to indicate a statistically significant difference. altered compared with that in the untreated HCT-8/5-Fu cells (ratio: 1.00); however, this ratio was markedly increased in the curcumin + 5-FU treatment group (ratio: 3.64). Similar results were obtained following western blot analysis of the protein levels ( Fig. 3B and C) . Together, these results indicated that treatment with curcumin alone did not alter the levels of apoptosis in HCT-8/5-Fu cells, as the expression ratio of Bax/Bcl-2 was relatively unchanged compared with that in normal HCT-8/5-Fu cells. However, HCT-8/5-Fu cells treated with curcumin and 5-Fu combined exhibited a markedly increased rate of apoptosis compared with that in normal cells due to the significantly increased expression ratio of Bax/Bcl-2. (Fig. 3D) . The expression of these proteins was then further evaluated at the mRNA and protein levels in HCT-8/5-Fu cells with or without treatment. As shown in Fig. 3A , the mRNA expression level of Keap1 was not altered in cells exposed to curcumin treatment alone compared with that in normal cells, whereas treatment with 5-Fu alone or together with curcumin significantly induced the mRNA expression of Keap1 (P<0.005). By contrast, the mRNA expression level of Nrf2 was markedly upregulated in cells treated with curcumin or 5-Fu only, compared with that in normal cells, whereas combined treatment with 5-Fu and curcumin significantly suppressed the mRNA expression of Nrf2 (P<0.005). Similar results were obtained following western blot analysis of the protein levels ( Fig. 3B and C) . Furthermore, upregulation of the protein expression level of Nrf2 was observed in HCT-8/5-Fu cells following treatment with a gradient of curcumin concentrations (1, 10 and 20 µM) compared with that in normal cells (Fig. 3E) . A previous report demonstrated that Nrf2 was able to directly activate the transcription of the anti-apoptotic protein Bcl-2, whereas Keap1 induced Bcl-2 ubiquitination via Cullin 3 (Cul3) and stabilized Bax (21, 22) . The results of the present study indicated that curcumin significantly repressed the mRNA and protein expression levels of Nrf2 following combined treatment with 5-Fu in HCT-8/5-Fu cells, leading to reduced mRNA and protein expression levels of Bcl-2, which induced cell apoptosis further.
Results
Curcumin enhances the chemosensitivity of HCT-8/5-Fu cells
Nrf2 is a key factor in determining the MDR reversal effect of curcumin in HCT-8/5-Fu cells.
To investigate whether Nrf2 has a functional role in determining the MDR reversal effect of curcumin in HCT-8/5-Fu cells, the present study first reduced the expression of Nrf2 at the mRNA and protein levels in the HCT-8/5-Fu cells using a siNrf2 (Fig. 4A and B) , as in our previous report (23) . The expression of Bcl-2 was reduced at the mRNA and protein levels in cells treated with siNrf2 compared with cells transfected with siCtrl only, however, the expression of Keap1 was not altered and the expression level of Bax was increased (Fig. 4B and C) . These results confirmed that Nrf2 directly promoted the expression of Bcl-2 at the mRNA and protein levels. Subsequently, the present study examined the cytotoxicity of 5-Fu towards HCT-8/5-Fu cells treated with siNrf2 or siRNA alone using MTT assays. The results revealed that cells treated with siNrf2 (IC 50 : 0.7469±0.02321 mM) were more sensitive to 5-Fu than cells treated with siCtrl (IC 50 : 15.20±0.1362 mM; Fig. 4D ). Taken together, these results indicated that the effect of siNrf2 combined with 5-Fu treatment in HCT-8/5-Fu cells was similar to that observed in cells treated with curcumin combined with 5-Fu, leading to the reduced expression of Nrf2 at the mRNA and protein levels, which further suppressed the expression levels of Bcl-2, thereby promoting apoptosis to reverse MDR.
Discussion
Chemotherapy with cytotoxic drugs is essential in cancer treatment and is often used following surgery as an adjuvant Cell viability was measured using a 3-(4,5-dimethyl-2-thiazol)-2,5-diphenyltetrazolium bromide assay. Nrf2, nuclear factor erythroid 2-related factor; MDR, multidrug resistance; si-, small interfering RNA; Ctrl, negative control; Bcl-2, B-cell lymphoma 2; Bax, Bcl-2-associated X protein; Keap1, Kelch like ECH associated protein 1. therapy in treating patients with advanced colon cancer (24) . However, drug resistance develops in almost all patients with colon cancer, which leads to chemotherapy failure (3). Therefore, screening effective MDR reversal agents, and combining them with cytotoxic drugs has been a promising strategy to overcome MDR and thereby improve the therapeutic efficacies of MDR in cancer (25) . Over several decades, compounds, including verapamil, cyclosporine, quinidine and tamoxifen, have exhibited MDR reversal activity in vitro. However, these compounds have limited clinical applications due to their high toxicity and low activity (25) . A number of studies have reported that curcumin can reverse MDR by regulating the expression of genes involved in drug efflux transport and apoptosis in a variety of MDR cancer cells, and exhibit low toxicity and high activity (26) (27) (28) . Therefore, a comprehensive understanding of the underlying mechanisms of curcumin is critical for the development and improvement of novel treatment strategies for patients with MDR.
A previous study suggested that curcumin may reverse the MDR of HCT-8/5-Fu cells by decreasing the expression levels of several genes involved in the drug efflux pump and in apoptosis, including p-glycoprotein, heat shock protein 27, survivin, and Bcl-2 (29) . However, the majority of the previous studies have focused on the regulatory effect of curcumin on the expression of Bcl-2 in human cancer cells, including colorectal cancer, hepatoma, renal carcinoma and glioblastoma cells (30) (31) (32) (33) . In the present study, the regulatory effect of curcumin in MDR cells was also investigated, and a significant increase in apoptosis was observed only in cells treated with curcumin and 5-Fu combined; treatment with curcumin or 5-Fu alone did not markedly induce apoptosis compared with that in the untreated control cells. To confirm these results, the expression of Bcl-2 and Bax at the mRNA and protein levels was determined; the expression ratio of Bcl-2/Bax was relatively unchanged in cells treated with curcumin or 5-Fu alone compared with that in untreated control cells. By contrast, this ratio was markedly reduced in cells treated with curcumin and 5-Fu in combination. Taken together, these results demonstrated that combined treatment with curcumin and 5-Fu in HCT-8/5-Fu cells significantly decreased the expression ratio of Bcl-2/Bax compared with that in untreated control cells, which in turn increased the levels of apoptosis. However, treatment with curcumin alone in HCT-8/5-Fu cells did not induce apoptosis compared with that in untreated control cells as curcumin had no effect on the expression ratio of Bcl-2/Bax.
A previous study described an important connection between the Keap1/Nrf2 signaling pathway and the Bcl-2 family. Keap1 directly binds to the BH2 domain of Bcl-2 and induces its ubiquitination via Cul3 in a conserved lysine residue, which then triggers Bcl-2 proteasomal degradation (21) . In addition, Nrf2 is able to directly activate the transcription of the antiapoptotic proteins Bcl-2 and Bcl-extra large, resulting in increased cell survival and drug resistance (19, 22) . Taken together, these results demonstrated that apoptosis is inhibited via the activation of Nrf2 and, in turn, high levels of functional Keap1 (and therefore inactive Nrf2) result in its induction by proapoptotic proteins. Therefore, the present study examined the expression levels of Nrf2 and other reference proteins between HCT-8 and HCT-8/5-Fu cells. It was found that the expression of Nrf2 was upregulated in In conclusion, the present study confirmed the reversal effect of curcumin on MDR in HCT-8/5-Fu cells and demonstrated for the first time, to the best of our knowledge, the favorable effect of Nrf2 in the MDR reversal effect of curcumin in colorectal cancer cells. Curcumin, at a non-cytotoxic dose, combined with 5-Fu induced apoptosis by decreasing the expression of Nrf2, which in turn suppressed the expression ratio of Bcl-2/Bax, and consequently reversed the MDR of HCT-8/5-Fu cells. Therefore, the combination of curcumin with cytotoxic drugs may serve as a promising strategy for chemotherapy in patients with colorectal cancer. the manuscript. LJH performed the MTT assays and wrote the manuscript. HZY performed the apoptosis and western blot assays. DFL performed the RNA interference assays. YBZ performed the reverse transcription-quantitative polymerase chain reaction assays. DDM and SPZ performed cell cultures. YYC and YWJ performed cell culture and drug treatment assays. JS performed quantification of protein expression levels from western blots using ImageJ software. All authors read and approved the final manuscript.
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